Preclinical models looking for synergy have shown positive effects combining CDK4/6i with inhibitors targeting molecules such as EGFR, MEK, mTOR or BRAF V600E in various cancers, as well as the ability to overcome resistance [11–14]. The gene discussed is MAP2K7; the disease is cancer.